270 related articles for article (PubMed ID: 33210570)
1. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V; Griesshammer M; Martino B; Foltz L; Tavares R; Al-Ali HK; Giraldo P; Guglielmelli P; Lomaia E; Bouard C; Paley C; Tiwari R; Zor E; Raanani P
Leuk Lymphoma; 2021 Apr; 62(4):918-926. PubMed ID: 33210570
[TBL] [Abstract][Full Text] [Related]
2. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
[TBL] [Abstract][Full Text] [Related]
4. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P; Griesshammer M; Guglielmelli P; Bouard C; Paley C; Tiwari R; Vannucchi AM
Hematol Oncol; 2021 Oct; 39(4):558-566. PubMed ID: 34224180
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
8. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
9. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
11. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
12. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
13. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Yacoub A; Borate U; Rampal RK; Ali H; Wang ES; Gerds AT; Hobbs G; Kremyanskaya M; Winton E; O'Connell C; Goel S; Oh ST; Schiller G; McCloskey J; Palmer J; Holmes H; Hager S; Assad A; Erickson-Viitanen S; Zhou F; Daver N
Blood Adv; 2024 Mar; 8(6):1515-1528. PubMed ID: 38290135
[TBL] [Abstract][Full Text] [Related]
16. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
17. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
18. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Verstovsek S; Kiladjian JJ; Vannucchi AM; Mesa RA; Squier P; Hamer-Maansson JE; Harrison C
Cancer; 2023 Jun; 129(11):1681-1690. PubMed ID: 36840971
[TBL] [Abstract][Full Text] [Related]
19. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of ruxolitinib in patients with myelofibrosis: a single-center retrospective analysis].
Edahiro Y; Komatsu N
Rinsho Ketsueki; 2019; 60(7):755-760. PubMed ID: 31391362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
